uniQure Faces Securities Class Action Investigation
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 4 days ago
0mins
Should l Buy QURE?
Source: Businesswire
- Investigation Launched: Faruq & Faruq LLP is investigating potential claims against uniQure N.V., reminding investors to apply for lead plaintiff status by April 13, 2026, indicating significant legal risks that may undermine shareholder confidence.
- FDA Approval Issues: The complaint alleges that uniQure's pivotal study design was not fully approved by the FDA, and the company failed to disclose this information adequately, leading to investor misconceptions about the company's future prospects and potentially affecting its ability to raise funds.
- Stock Price Plunge: On November 3, 2025, uniQure's stock price plummeted by 49%, from $67.69 to $34.29, after the FDA stated it no longer agreed that the data would support a BLA submission, reflecting strong market concerns about the company's future and potential severe investor losses.
- Legal Implications: The lead plaintiff will oversee the litigation, and any potential recovery will impact all shareholders, highlighting that deficiencies in corporate governance and transparency could lead to broader legal and financial repercussions.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy QURE?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on QURE
Wall Street analysts forecast QURE stock price to rise
10 Analyst Rating
8 Buy
2 Hold
0 Sell
Strong Buy
Current: 22.370
Low
33.00
Averages
49.88
High
70.00
Current: 22.370
Low
33.00
Averages
49.88
High
70.00
About QURE
Uniqure NV is a company based in the Netherlands specialized in gene therapy. It seeks to develop one-time administered treatments with potentially curative results for patients suffering from genetic and other devastating diseases. It develops, both internally and through partnerships, a pipeline of gene therapies. It produces adeno-associated virus based, or AAV-based, gene therapies in its own facilities with a proprietary, commercial-scale, current good manufacturing practices, compliant, manufacturing process. AMT-061, the Company’s lead product candidate for patients with hemophilia B, is going through a dosing phase of a pivotal study. AMT-130, the product candidate for patients with Huntington’s disease is in Phase I/II clinical study.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
uniQure Investors Encouraged to Seek Legal Options
- Legal Claim Investigation: Faruqi & Faruqi LLP is investigating potential claims against uniQure N.V., particularly for investors who suffered losses exceeding $100,000 between September 24, 2025, and October 31, 2025, indicating possible legal liabilities for the company.
- FDA Approval Issues: The complaint alleges that uniQure and its executives violated federal securities laws by failing to disclose that the design of their pivotal study was not fully approved by the FDA, which could lead to delays in future BLA submissions and impact the company's business outlook.
- Stock Price Plunge Impact: On November 3, 2025, uniQure's stock price plummeted by 49%, dropping from $67.69 to $34.29, following the FDA's statement that it no longer agreed with the adequacy of the data, reflecting strong market concerns about the company's prospects.
- Investor Action Call: Faruqi & Faruqi LLP encourages anyone with information, including former employees and shareholders, to contact them to provide insights, indicating the firm's proactive approach to seeking legal accountability for uniQure's actions.
See More
Class Action Reminder for uniQure N.V. Shareholders
- Lawsuit Background: Robbins LLP reminds all investors who purchased uniQure N.V. (NASDAQ:QURE) ordinary shares between September 24, 2025, and October 31, 2025, that a class action has been filed, alleging the company misled investors regarding the likelihood of FDA approval for its drug candidate.
- FDA Feedback Impact: On November 3, 2025, uniQure revealed that the FDA indicated its pivotal study design was not fully approved, necessitating a delay in the BLA submission timeline, which directly affected the company's stock price.
- Stock Price Plunge: Following the announcement, uniQure's stock price plummeted by $33.40, a drop of over 49%, from a closing price of $67.69 on October 31, 2025, to $34.29, reflecting strong market concerns about the company's future prospects.
- Investor Action: Shareholders wishing to serve as lead plaintiffs in the class action must submit their papers by April 13, 2026, indicating their representation of other shareholders' interests, while those who choose not to participate can remain absent class members and retain their rights to recovery.
See More
Class Action Lawsuit Announced for uniQure N.V.
- Class Action Initiation: Rosen Law Firm has announced a class action lawsuit on behalf of investors who purchased uniQure N.V. shares between September 24 and October 31, 2025, indicating significant legal risks that may undermine shareholder confidence.
- Compensation Structure: Investors may receive compensation without any out-of-pocket costs through a contingency fee arrangement, which could encourage more affected shareholders to participate, thereby amplifying the lawsuit's impact.
- Details of Allegations: The lawsuit alleges that uniQure misrepresented the approval status of its pivotal study by the FDA, which could delay its Biologics License Application, thereby affecting the company's future market prospects and operational credibility.
- Law Firm Credentials: Rosen Law Firm is recognized for its successful track record in securities class actions, having recovered over $438 million for investors in 2019 alone, which may bolster investor confidence in the potential outcomes of this lawsuit.
See More
uniQure Faces Class Action Lawsuit Warning
- Class Action Reminder: The Schall Law Firm alerts investors of a class action lawsuit against uniQure N.V. for violations of securities laws related to trades from September 24 to October 31, 2025, potentially impacting investor rights.
- False Statement Allegations: The complaint alleges that uniQure made false and misleading statements, failing to secure full FDA approval for its pivotal study, resulting in investor losses once the truth emerged.
- Legal Consultation Opportunity: Investors are encouraged to contact the Schall Law Firm before April 13, 2026, to discuss their rights and participate in the lawsuit, with free consultations available.
- Lawsuit Certification Status: The class action has not yet been certified, meaning investors are not represented by an attorney until certification occurs, and those who choose not to act will remain absent class members.
See More
uniQure Faces Class Action Lawsuit Over Misleading Statements
- Class Action Filed: Berger Montague PC has announced a class action lawsuit against uniQure on behalf of investors who acquired securities between September 24, 2025, and October 31, 2025, highlighting significant investor concerns regarding the company's transparency.
- Stock Price Volatility: On September 24, 2025, uniQure's stock surged from $13.66 to $47.50, a nearly 250% increase, but plummeted over 49% to $34.29 on November 3, 2025, after news that FDA agreement on study design was not finalized, indicating a loss of market confidence.
- FDA Approval Uncertainty: The lawsuit alleges that uniQure misled investors about the effectiveness of its gene therapy candidate AMT-130 and the likelihood of accelerated FDA approval, resulting in significant financial losses for investors who made decisions based on misleading information.
- Investor Rights Protection: Investors must apply by April 13, 2026, to be appointed as lead plaintiffs in the class action, reflecting a growing emphasis on corporate governance and transparency that could impact future investor confidence and the company's reputation.
See More
Class Action Lawsuit Filed Against uniQure N.V.
- Class Action Initiation: Rosen Law Firm has filed a class action lawsuit on behalf of investors who purchased uniQure N.V. shares between September 24 and October 31, 2025, with a deadline of April 13, 2026, for potential lead plaintiffs, highlighting the urgency and compensation opportunities for affected investors.
- Lawsuit Background: The lawsuit alleges that uniQure failed to disclose that its pivotal study design for a leading drug candidate was not fully approved by the FDA, leading to a lack of reasonable basis for investors' assessments of the company's prospects, potentially resulting in financial losses.
- Law Firm Credentials: Rosen Law Firm is renowned for its successful track record in securities class actions, having recovered over $438 million for investors in 2019 alone, demonstrating its strength and experience in handling similar cases effectively.
- Investor Action Guidance: Investors can obtain more information by visiting the designated website or calling a toll-free number, emphasizing the ease of participation in the class action and the potential legal support available, encouraging investors to take action to protect their rights.
See More
uniQure Investors Encouraged to Seek Legal Options
- Legal Claim Investigation: Faruqi & Faruqi LLP is investigating potential claims against uniQure N.V., particularly for investors who suffered losses exceeding $100,000 between September 24, 2025, and October 31, 2025, indicating possible legal liabilities for the company.
- FDA Approval Issues: The complaint alleges that uniQure and its executives violated federal securities laws by failing to disclose that the design of their pivotal study was not fully approved by the FDA, which could lead to delays in future BLA submissions and impact the company's business outlook.
- Stock Price Plunge Impact: On November 3, 2025, uniQure's stock price plummeted by 49%, dropping from $67.69 to $34.29, following the FDA's statement that it no longer agreed with the adequacy of the data, reflecting strong market concerns about the company's prospects.
- Investor Action Call: Faruqi & Faruqi LLP encourages anyone with information, including former employees and shareholders, to contact them to provide insights, indicating the firm's proactive approach to seeking legal accountability for uniQure's actions.
See More
Class Action Reminder for uniQure N.V. Shareholders
- Lawsuit Background: Robbins LLP reminds all investors who purchased uniQure N.V. (NASDAQ:QURE) ordinary shares between September 24, 2025, and October 31, 2025, that a class action has been filed, alleging the company misled investors regarding the likelihood of FDA approval for its drug candidate.
- FDA Feedback Impact: On November 3, 2025, uniQure revealed that the FDA indicated its pivotal study design was not fully approved, necessitating a delay in the BLA submission timeline, which directly affected the company's stock price.
- Stock Price Plunge: Following the announcement, uniQure's stock price plummeted by $33.40, a drop of over 49%, from a closing price of $67.69 on October 31, 2025, to $34.29, reflecting strong market concerns about the company's future prospects.
- Investor Action: Shareholders wishing to serve as lead plaintiffs in the class action must submit their papers by April 13, 2026, indicating their representation of other shareholders' interests, while those who choose not to participate can remain absent class members and retain their rights to recovery.
See More
Class Action Lawsuit Announced for uniQure N.V.
- Class Action Initiation: Rosen Law Firm has announced a class action lawsuit on behalf of investors who purchased uniQure N.V. shares between September 24 and October 31, 2025, indicating significant legal risks that may undermine shareholder confidence.
- Compensation Structure: Investors may receive compensation without any out-of-pocket costs through a contingency fee arrangement, which could encourage more affected shareholders to participate, thereby amplifying the lawsuit's impact.
- Details of Allegations: The lawsuit alleges that uniQure misrepresented the approval status of its pivotal study by the FDA, which could delay its Biologics License Application, thereby affecting the company's future market prospects and operational credibility.
- Law Firm Credentials: Rosen Law Firm is recognized for its successful track record in securities class actions, having recovered over $438 million for investors in 2019 alone, which may bolster investor confidence in the potential outcomes of this lawsuit.
See More
uniQure Faces Class Action Lawsuit Warning
- Class Action Reminder: The Schall Law Firm alerts investors of a class action lawsuit against uniQure N.V. for violations of securities laws related to trades from September 24 to October 31, 2025, potentially impacting investor rights.
- False Statement Allegations: The complaint alleges that uniQure made false and misleading statements, failing to secure full FDA approval for its pivotal study, resulting in investor losses once the truth emerged.
- Legal Consultation Opportunity: Investors are encouraged to contact the Schall Law Firm before April 13, 2026, to discuss their rights and participate in the lawsuit, with free consultations available.
- Lawsuit Certification Status: The class action has not yet been certified, meaning investors are not represented by an attorney until certification occurs, and those who choose not to act will remain absent class members.
See More
uniQure Faces Class Action Lawsuit Over Misleading Statements
- Class Action Filed: Berger Montague PC has announced a class action lawsuit against uniQure on behalf of investors who acquired securities between September 24, 2025, and October 31, 2025, highlighting significant investor concerns regarding the company's transparency.
- Stock Price Volatility: On September 24, 2025, uniQure's stock surged from $13.66 to $47.50, a nearly 250% increase, but plummeted over 49% to $34.29 on November 3, 2025, after news that FDA agreement on study design was not finalized, indicating a loss of market confidence.
- FDA Approval Uncertainty: The lawsuit alleges that uniQure misled investors about the effectiveness of its gene therapy candidate AMT-130 and the likelihood of accelerated FDA approval, resulting in significant financial losses for investors who made decisions based on misleading information.
- Investor Rights Protection: Investors must apply by April 13, 2026, to be appointed as lead plaintiffs in the class action, reflecting a growing emphasis on corporate governance and transparency that could impact future investor confidence and the company's reputation.
See More
Class Action Lawsuit Filed Against uniQure N.V.
- Class Action Initiation: Rosen Law Firm has filed a class action lawsuit on behalf of investors who purchased uniQure N.V. shares between September 24 and October 31, 2025, with a deadline of April 13, 2026, for potential lead plaintiffs, highlighting the urgency and compensation opportunities for affected investors.
- Lawsuit Background: The lawsuit alleges that uniQure failed to disclose that its pivotal study design for a leading drug candidate was not fully approved by the FDA, leading to a lack of reasonable basis for investors' assessments of the company's prospects, potentially resulting in financial losses.
- Law Firm Credentials: Rosen Law Firm is renowned for its successful track record in securities class actions, having recovered over $438 million for investors in 2019 alone, demonstrating its strength and experience in handling similar cases effectively.
- Investor Action Guidance: Investors can obtain more information by visiting the designated website or calling a toll-free number, emphasizing the ease of participation in the class action and the potential legal support available, encouraging investors to take action to protect their rights.
See More
